



TESARO, Inc.
Investor Relations Department
1000 Winter St., Ste. 3300
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: TSRO

Last Trade: 146.72

Trade Time: 4:15 PM ET
6/23/2017

Change: -3.05  (-2.036%)

Day Range 146.17 - 153.25

52-Week Range 36.71 - 192.94


Volume 4,154,306

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Founded in 2010, TESARO is a publicly-traded oncology focused company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates. Upon successful development and regulatory approval of any of our product candidates, TESARO intends to make them available to cancer patients in North America, Europe and China through its own commercialization efforts and to establish a network of licensees and distributors in other geographic areas. For more information... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 6/07/2017 [TESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference](#)
- 6/03/2017 [TESARO Provides Business and Pipeline Update at ASCO Investor Briefing](#)
- 5/25/2017 [TESARO Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- 5/22/2017 [National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community](#)
- 5/11/2017 [TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer](#)

Financials [\[View all \]](#)

- 2/28/2017 [Annual Report \(10-K\)](#)
- 4/07/2017 [Proxy Statement \(DEF 14A\)](#)
- 5/09/2017 [Quarterly Report \(10-Q\)](#)
- 11/04/2016 [Quarterly Report \(10-Q\)](#)
- 8/05/2016 [Quarterly Report \(10-Q\)](#)